Barclays lowered the firm’s price target on Catalent to $50 from $55 and keeps an Equal Weight rating on the shares. The analyst previewed the Q3 earnings reports for the life science tools and diagnostics sector and dug into bioprocessing destocking and the risk of National Institutes of Health budget cuts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTLT:
- Melt announces exclusive development and license pact with Catalent for Zydis
- Catalent (NYSE:CTLT) Receives NYSE Non-Compliance Notice
- Catalent upgraded to Buy at Argus on strong growth outlook for FY24
- Catalent upgraded to Buy from Hold at Argus
- Catalent price target raised to $55 from $42 at Barclays